NewsBenzingaHC Wainwright & Co. bestätigt Kaufempfehlung für NeuroSense Therapeutics und erhöht das Kursziel auf 52 US-Dollar HC Wainwright & Co. bestätigt Kaufempfehlung für NeuroSense Therapeutics und erhöht das Kursziel auf 52 US-Dollar Benzinga 2026.09.28 10:20 (GMT+0) Open on Benzinga Other news Oracle Announces Non-Binding Agreement With AstraZeneca To Explore AI And Real-World Data For Clinical Trial Patient Identification, Evidence Generation And Care Insights Palantir: Higher Fair Value, But Not Enough (NASDAQ:PLTR) Ambarella: The Biggest AI Growth Opportunity Is Still Ahead (NASDAQ:AMBA) Alphabet's President of Global Affairs and Chief Legal Officer dismisses Europe's concerns over US dominance in AI Activist Investor Starboard Takes Stake in Solstice, Demands $100M in Cost Cuts - TipRanks.com Gold (XAU:USD) Technical And Macro Outlook: October 2026
Oracle Announces Non-Binding Agreement With AstraZeneca To Explore AI And Real-World Data For Clinical Trial Patient Identification, Evidence Generation And Care Insights
Alphabet's President of Global Affairs and Chief Legal Officer dismisses Europe's concerns over US dominance in AI
